Arcturus Therapeutics Holdings Inc

NASDAQ:ARCT   1:15:56 PM EDT
60.82
-1.45 (-2.33%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.57B
Current PEN/A
Forward PE N/A
2yr Forward PE 3041
See more stats
Estimates Current Quarter
Revenue$2.33 Million
Adjusted EPS-$0.87
See more estimates
10-Day MA$64.13
50-Day MA$74.29
200-Day MA$51.38
See more pivots

Arcturus Therapeutics Ltd. Stock, NASDAQ:ARCT

10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA 92121
Israel
Phone: 858-900-2660
Number of Employees: 72

Description

Alcobra Ltd., a biopharmaceutical company, focuses on the development and commercialization of oral drug candidates. The company is primarily developing MDX (metadoxine), an onset/extended release formulation of the chemical pyridoxine pyroglutamate, which is in Phase III clinical trial for adults with attention deficit hyperactivity disorder (ADHD); in Phase II clinical trial for pediatric with ADHD; and which is completed Phase II clinical trial in adolescents and adults with Fragile X Syndrome. Alcobra Ltd. was founded in 2008 and is headquartered in Tel Aviv, Israel.